

LS-01 Luncheon Seminar 01**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 01 (Osaka International Convention Center 5F Large Hall)

Learning from Charcot: Integration of clinical neurology and neuropathology

Chair : Makoto Iwata

Medical Clinic Kakinokizaka, Japan

LS-01-1 The medical students who asked me to read Charcot

Hideki Mochizuki

Department of Neurology, Osaka University Graduate School of Medicine, Japan

LS-01-2 Alzheimer's Disease: From Symptomatic Treatment To Disease Modification

Takeshi Iwatsubo

National Institute of Neuroscience National Center of Neurology and Psychiatry, Japan

Sponsored by: Eli Lilly Japan K.K.

LS-02 Luncheon Seminar 02**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 03 (Osaka International Convention Center 10F Conference Room 1003)

Digital Transformation in MS Care: Challenges Faced by Specialists

Chair : Noriko Isobe

Graduate School of Medical Sciences, Kyushu University, Japan

LS-02-1 Advancing Equity in Specialized Multiple Sclerosis Care

Norio Chihara

Kobe University Graduate School of Medicine, Japan

LS-02-2 The Potential of Digital Tools in Multiple Sclerosis Care: A Challenge Toward Medical Standardization

Yusei Miyazaki

NHO Hokkaido Medical Center, Japan

Sponsored by: Novartis Pharma K.K.

LS-03 Luncheon Seminar 03**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 04 (Osaka International Convention Center 10F Conference Room 1001-1002)

The Frontline of Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy

Chair : Atsushi Takeda

Department of Neurology, NHO Sendai-Nishitaga Hospital, Japan

LS-03-1 Noriko Nishikawa

Department of Neurology, Juntendo University School of Medicine, Japan

Sponsored by: AbbVie GK

LS-04 Luncheon Seminar 04**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 05 (Osaka International Convention Center 10F Conference Room 1009)

Post-stroke epilepsy: an old and new problem

Chair : Masafumi Ihara

National Cerebral and Cardiovascular Center, Japan

LS-04-1**Hajime Yoshimura**

Kobe City Medical Center General Hospital, Japan

Sponsored by: DAIICHI SANKYO Co. Ltd. / UCB Japan Co. Ltd.

LS-05 Luncheon Seminar 05**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 06 (Osaka International Convention Center 10F Conference Room 1008)

Consider SMA as a systemic disease

Chair : Akihiro Hashiguchi

National Okinawa Hospital, Neurology, Japan

LS-05-1**A deeper understanding of SMN-loss pathology****Kentaro Sahashi**

Nagoya University Graduate School of Medicine, Department of Neurology, Japan

LS-05-2**Treatment strategies for SMA as a systemic disease****Akihiro Hashiguchi**

National Okinawa Hospital, Neurology, Japan

Sponsored by: Chugai Pharmaceutical Co., Ltd.

LS-06 Luncheon Seminar 06**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 07 (Osaka International Convention Center 12F Conference Hall)

**Diagnosis and treatment of SOD1-ALS: up to date
~ To avoid missing any treatment opportunity~**

Chair : Yuishin Izumi

Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Japan

LS-06-1**The Changing Landscape of ALS Treatment with Nucleic Acid
Therapy ~ To Avoid Missing SOD1-ALS Cases ~****Makoto Urushitani**

Department of Neurology, Shiga University of Medical Science, Japan

LS-06-2**Natural History of SOD1-ALS and Possibility of Treatment with
Tofersen****Seiichi Nagano**

Department of Neuro-developmental and -degenerative Disease Research, United Graduate School of Child Development, Osaka University, Japan

Sponsored by: Biogen Japan Ltd.

LS-07 Luncheon Seminar 07**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 09 (Osaka International Convention Center 12F Conference Room 1202)

Reconsideration of gMG treatment issues

Chair : Tomihiro Imai

Centre for Neuromuscular and Intractable Diseases, National Hakone Hospital, Japan

LS-07-1**Shigeaki Suzuki**

Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan

Sponsored by: Medical Affairs Division, Janssen Pharmaceutical K.K.

LS-08 Luncheon Seminar 08**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 10 (Osaka International Convention Center 11F Conference Room 1101-1102)

Importance of oral antiparkinsonian agents dosing design for optimizing levodopa pharmacokinetics

Chair : Mutsumi Iijima

Department of Neurology, Tokyo Women's Medical University, Japan

LS-08-1**Masahiro Nagai**

Department of Neurology and Clinical Pharmacology, Ehime University Hospital, Japan

Sponsored by: ONO PHARMACEUTICAL CO., LTD.

LS-09 Luncheon Seminar 09**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 11 (Osaka International Convention Center 8F Conference Room 801-802)

Thinking about the Future of Migraine Treatment

Chair : Noboru Imai

Department of Neurology, Headache Center, Japanese Red Cross Shizuoka Hospital, Japan

LS-09-1~~Treatment Strategies with CGRP Monoclonal Antibodies Emerging from Clinical Trials and Real-World Data~~~~Shiho Suzuki~~**Withdrawal**~~Department of Neurology, Dokkyo Medical University, Japan~~**LS-09-2****Thinking About Migraine Pain×non-Pain****- A Future Perspective Including Total Care with Comorbidities****Daisuke Danno**

Department of Neurology, Headache Center, Tominaga Hospital, Japan

Sponsored by: Otsuka Pharmaceutical Co.,Ltd.

LS-10 Luncheon Seminar 10**Jp**

May 21 (Wed) 12:05 ~ 13:05 Room 12 (Osaka International Convention Center 7F Conference Room 701-702)

Strategies for the Treatment of Chronic Constipation in Parkinson's Disease Patients - Focusing on IBAT Inhibitors-

Chair : Takafumi Hasegawa

National Hospital Organization SENDAI NISHITAGA HOSPITAL, Japan

LS-10-1**Atsushi Nakajima**

Yokohama City University School of Medicine, Japan

Sponsored by: EA Pharma Co., Ltd. / MOCHIDA PHARMACEUTICAL CO., LTD

LS-11 Luncheon Seminar 11**Jp**

May 21 (Wed) 12:05 ~ 13:05

Room 13 (RIHGA Royal Hotel Osaka 3F Korin 1)

The significance of anti-A β antibody therapy based on cutting-edge amyloid research

Chair : Masahisa Katsuno

Department of Neurology, Nagoya University Graduate School of Medicine,
Japan**LS-11-1****Kenjiro Ono**

Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Japan

Sponsored by: Eisai Co., Ltd. Medical HQs / Biogen Japan Ltd., Medical

LS-12 Luncheon Seminar 12**Jp**

May 21 (Wed) 12:05 ~ 13:05

Room 14 (RIHGA Royal Hotel Osaka 3F Korin 2)

Relationship between Neuromyelitis Optica Spectrum Disorder and B-cell Therapy

Chairs : Koji Shinoda

Department of Neurology, Graduate School of Medical Sciences, Kyushu
University, Japan

Kenzo Sakurai

Department of Neurology, St. Marianna University School of Medicine, Japan

LS-12-1**The Future Map for NMO patients Drawn by Biologics****Kenzo Sakurai**

Department of Neurology, St. Marianna University School of Medicine, Japan

LS-12-2**B-cell targeted therapy for NMO****-The latest topics on mechanism of action-****Koji Shinoda**

Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Japan

Sponsored by: Mitsubishi Tanabe Pharma Corporation

LS-13 Luncheon Seminar 13**Jp**

May 21 (Wed) 12:05 ~ 13:05

Room 15 (RIHGA Royal Hotel Osaka 3F Korin 3)

Treatment strategies based on the pathophysiology of CIDP

Chair : Haruki Koike

Division of Neurology, Department of Internal Medicine, Faculty of Medicine,
Saga University, Japan**LS-13-1****The Journey of Evidence for CIDP: Past, Present, and Beyond****Sonoko Misawa** Department of Neurology and Neurological Science, Institute of Science Tokyo
~~Department of Neurology, Chiba University Graduate School of Medicine, Japan~~**LS-13-2****Pathogenesis and Treatment Strategies for CIDP: Perspectives on the Blood-Nerve Barrier****Yukio Takeshita**Department of Neurotherapeutics, BBB research center, Yamaguchi University School of
Medicine, Japan

Sponsored by: CSL Behring K.K.

LS-14 Luncheon Seminar 14**Jp**

May 22 (Thu) 12:00 ~ 13:00

Room 01 (Osaka International Convention Center 5F Large Hall)

**Spinning the Aspirations of Koan Ogata ~ New History of
Complement-Targeted Therapy in MG and NMOSD ~**

Chairs : Masanori Takahashi

Clinical Neurophysiology, Dept. Clinical Laboratory and Biomedical Sciences,
Osaka University Graduate School of Medicine, Japan**Jin Nakahara**

Department of Neurology, Keio University School of Medicine, Japan

Okuno Tatsusada

Department of Neurology, Osaka University, Japan

LS-14-1**NMOSD: Complementopathy and Precision Medicine****Jin Nakahara**

Department of Neurology, Keio University School of Medicine, Japan

LS-14-2**The Progress of MG Treatment and New Therapeutics****Masanori Takahashi**Clinical Neurophysiology, Dept. Clinical Laboratory and Biomedical Sciences, Osaka University
Graduate School of Medicine, Japan**LS-14-3****Koan Ogata as Medical scientist & physician****Takeru Kaido**

Author, M.D., Visiting Professor, Fukui Prefectural University, Japan

Sponsored by: Alexion Pharmaceuticals, Inc.

21

22

Sponsored Seminar

LS-15 Luncheon Seminar 15**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 03 (Osaka International Convention Center 10F Conference Room 1003)

Considering the Meaningful Benefit of Anti-amyloid- β Antibody Therapy

Chair : Kenjiro Ono

Department of Neurology and Neurobiology and Aging, Kanazawa University
Graduate School of Medical Sciences, Japan**LS-15-1****Masafumi Ihara**

Department of Neurology, National Cerebral and Cardiovascular Center, Japan

Sponsored by: Eli Lilly Japan K.K.

LS-16 Luncheon Seminar 16**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 04 (Osaka International Convention Center 10F Conference Room 1001-1002)

New trend in CIDP treatment

Chair : Satoshi Kuwabara

Department of Neurology, Chiba University Graduate School of Medicine,
Japan**LS-16-1****Kenichi Kaida**

Department of Neurology, Saitama Medical Center, Japan

LS-16-2**Motoi Kuwahara**

Department of Neurology, Kindai University Faculty of Medicine, Japan

Sponsored by: argenx Japan K.K.

LS-17 Luncheon Seminar 17**En**

May 22 (Thu) 12:00 ~ 13:00 Room 05 (Osaka International Convention Center 10F Conference Room 1009)

Early Recognition and Device-Aided Therapy: The New Wave in Parkinson's Treatment

Chair : Ritsuko Hanajima

Division of Neurology, Department of Brain and Neurosciences, Faculty of
Medicine, Tottori University, Japan**LS-17-1****Angelo Antonini**Parkinson and Movement Disorders Unit ERN-Rare Neurological Diseases Study Centre for
Neurodegeneration (CESNE) Department of Neuroscience, University of Padua, Italy

Sponsored by: AbbVie GK

LS-18 Luncheon Seminar 18**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 06 (Osaka International Convention Center 10F Conference Room 1008)

Landscape of Treatment and Evaluation for Spinal Muscular Atrophy

Chair : Hiroshi Takashima

Department of Neurology and Geriatrics, Kagoshima University Graduate
School of Medical and Dental Sciences, Japan**LS-18-1****Keita Takahashi**Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of
Medicine, Japan

Sponsored by: Biogen Japan Ltd.

LS-19 Luncheon Seminar 19**En**

May 22 (Thu) 12:00 ~ 13:00 Room 07 (Osaka International Convention Center 12F Conference Hall)

New Insights into Ofatumumab and Its Impact on MS Treatment

Chair : Mieko Ogino

International University of Health and Welfare, Japan

LS-19-1**New Insights into Ofatumumab and Its Impact on MS Treatment****Heinz Wiendl**

Freiburg University Hospital, Germany

Sponsored by: Novartis Pharma K.K.

LS-20 Luncheon Seminar 20**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 08 (Osaka International Convention Center 12F Grande Toque)

Role of amyloid PET before and after amyloid beta antibody therapy

Chair : Hisatomo Kowa

Kobe University Graduate School of Health Sciences, Japan

LS-20-1**Kenji Ishii**Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for
Geriatrics and Gerontology, Japan**LS-20-2****Hiroshi Matsuda**

Nippon Medical School Clinical Imaging Center, Japan

Sponsored by: PDRadiopharma

22

Sponsored Seminar

LS-21 Luncheon Seminar 21**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 09 (Osaka International Convention Center 12F Conference Room 1202)

The Impact of Somato-Cognitive Coordination Therapy Using Virtual Reality Technology on the Treatment of Neurological Disorders

Chair : Tomotaka Tanaka

National Cerebral and Cardiovascular Center, Japan

LS-21-1**Masahiko Hara**

Center for Community-Based Healthcare Research and Education, Shimane University Faculty of Medicine, Japan

Sponsored by: mediVR, inc.

LS-22 Luncheon Seminar 22**Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 10 (Osaka International Convention Center 11F Conference Room 1101-1102)

Basics and Up-to-Date of Management in MG

Chair : Hirofumi Ochi

Department of Intractable Disease and Aging Science, Ehime University
Graduate School of Medicine, Japan**LS-22-1****Mitsuru Watanabe**

Department of Neurology, Kyushu University Hospital, Japan

Sponsored by: Mitsubishi Tanabe Pharma Corporation Development & Medical
Affairs Division, Medical Affairs Department**LS-23 Luncheon Seminar 23****Jp**

May 22 (Thu) 12:00 ~ 13:00 Room 11 (Osaka International Convention Center 8F Conference Room 801-802)

ATTR Amyloidosis

Chair : Yukio Ando

SUGIMURAKAI MEDICAL ASSOCIATION SUGIMURA HOSPITAL, Japan

LS-23-1**The Importance and Practical Key Points of Early Diagnosis in Cardiac Amyloidosis****Fusako Sera**

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan

LS-23-2**Hereditary ATTR Amyloidosis: Current Status and Challenges****Mitsuharu Ueda**

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan

Sponsored by: Pfizer Japan Inc.

LS-24 Luncheon Seminar 24**En**

May 22 (Thu) 12:00 ~ 13:00 Room 12 (Osaka International Convention Center 7F Conference Room 701-702)

Appropriate use and future prospects of AD biomarkers

Chair : Manabu Ikeda

Department of Psychiatry, Osaka University Graduate School of Medicine,
Japan**LS-24-1**

Tobias Bittner

F.Hoffmann-LaRoche, Switzerland / Genentech, USA

LS-24-2

Takeshi Ikeuchi

Brain Research Institute, Niigata University, Japan

Sponsored by: Roche Diagnostics K.K.

LS-25 Luncheon Seminar 25**Jp**

May 22 (Thu) 12:00 ~ 13:00

Room 13 (RIHGA Royal Hotel Osaka 3F Korin 1)

g/MG molecular-targeted drugs: a wide range of options for self-administration [C5i™ZILBRYSQ® and anti-FcRn™RYSTIGGO®]

Chair : Shigeaki Suzuki

Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan

LS-25-1

Yuriko Nagane

General Hanamaki Hospital, Japan

LS-25-2

Hiroyuki Murai

Department of Neurology, International University of Health and Welfare, Japan

Sponsored by: UCB Japan Co. Ltd.

LS-26 Luncheon Seminar 26**Jp**

May 22 (Thu) 12:00 ~ 13:00

Room 14 (RIHGA Royal Hotel Osaka 3F Korin 2)

pharmacotherapy for Amyotrophic Lateral Sclerosis

Chair : Masashi Aoki

Department of Neurology, Tohoku University Graduate School of Medicine,
Professor, Japan**LS-26-1**

The development of high-dose methylcobalamin (Rozebalamin), a new treatment for ALS ~Early diagnosis becomes even more important~

Yuishin Izumi

Department of Neurology, Tokushima University Graduate School of Biomedical Sciences,
Professor, Japan

Sponsored by: Eisai Co., Ltd.

22

Sponsored Seminar

LS-27 Luncheon Seminar 27**En**

May 22 (Thu) 12:00 ~ 13:00

Room 15 (RIHGA Royal Hotel Osaka 3F Korin 3)

FUS and Movement Disorders

Chair : Ryosuke Takahashi

Kyoto University Research Administration Center, Japan

LS-27-1**FUS and Movement Disorders ~Essential Tremor and Parkinson's Disease, presented in an easy-to-understand manner~**

José A. Obeso

The University of Navarra Clinic, Spain

Sponsored by: InSightec Japan K.K.

LS-28 Luncheon Seminar 28**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 01 (Osaka International Convention Center 5F Large Hall)

Deciphering the mysteries of sleep: From fundamental neuroscience to real-world applications

Chair : Hideki Mochizuki

University of Tsukuba, International Institute for Integrative Sleep Medicine, Japan, Director and Professor

LS-28-1**Masashi Yanagisawa**

University of Tsukuba, International Institute for Integrative Sleep Medicine, Japan, Director and Professor

Sponsored by: Shionogi & Co.,Ltd.

LS-29 Luncheon Seminar 29**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 03 (Osaka International Convention Center 10F Conference Room 1003)

**Up-To-Date on Epilepsy Treatment
-The Key Points of New Anti-Seizure Medication**

Chair : Naoki Akamatsu

Department of Neurology, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE (IUHW) .SCHOOL OF MEDICINE, Japan

LS-29-1**Know-How and Essence of Epilepsy Treatment**

Taira Uehara

Department of Neurology, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE (IUHW).SCHOOL OF MEDICINE, Japan / Fukuoka Sanno Hospital, Japan

LS-29-2**What's the Difference in Levetiracetam and Brivaracetam?
~ Characteristics and Experiences ~**

Akihiro Shimotake

NHO Utano National Hospital, Department of Neurology and Clinical Research Center, Japan

Sponsored by: UCB Japan Co. Ltd.

22

23

Sponsored Seminar

LS-30 Luncheon Seminar 30**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 04 (Osaka International Convention Center 10F Conference Room 1001-1002)

Generalized myasthenia gravis treatment update

Chair : Kimiaki Utsugisawa

Department of Neurology, Hanamaki General Hospital, Japan

LS-30-1**Experience of VYVDURA treatment at Kumamoto University Hospital
- collaboration in the local area -**

Toshiya Nomura

Department of Neurology, Kumamoto University Hospital, Japan

LS-30-2**Optimizing cycle dosing intervals for Efgartigimod : to stabilize
symptom fluctuations**

Kazumasa Okada

Department of Neurology, Hospital of the University of Occupational and Environmental Health,
Japan

Sponsored by: argenx Japan K.K.

LS-31 Luncheon Seminar 31**En**

May 23 (Fri) 12:00 ~ 13:00 Room 05 (Osaka International Convention Center 10F Conference Room 1009)

Current Trends in Migraine Treatment

Chair : Takao Takeshima

Kotobuki Social Medical Corporation, Tominaga Hospital, Japan

LS-31-1**Current migraine Treatment: times have changed!**

Stewart J. Tepper

The New England Institute for Neurology and Headache Stamford, CT, USA

Sponsored by: Eli Lilly Japan K.K. / DAIICHI SANKYO COMPANY, LIMITED

LS-32 Luncheon Seminar 32**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 06 (Osaka International Convention Center 10F Conference Room 1008)

Advanced Parkinson's Disease

Chair : Hirohisa Watanabe

Department of Neurology, Fujita Health University, School of Medicine, Japan

LS-32-1**What are patients really telling us?****Pitfalls in the treatment of Parkinson's disease**

Takafumi Hasegawa

Department of Neurology/ Division of Clinical Research, National Hospital Organization Sendai
Nishitaga Hospital, Japan

Sponsored by: Medical Affairs, Kyowa Kirin Co., Ltd.

23

Sponsored Seminar

LS-33 Luncheon Seminar 33**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 07 (Osaka International Convention Center 12F Conference Hall)

The Importance of Evidence-Based Anti-CD20 Therapies

Chairs : Ryotaro Ikeguchi

Tokyo Women's Medical University, Japan

Makoto Kinoshita

Osaka University, Japan

LS-33-1 Early High Efficacy Therapy and Shared Decision Making

Yuji Tomizawa

Juntendo University Faculty of Medicine, Japan

LS-33-2 Ofatumumab Real World Data in 535 Japanese MS Patients

Takahiko Saida

Kansai MS Center/Irino Medical Clinic, Kyoto Miniren Chuo Hospital, Japan

Sponsored by: Novartis Pharma K.K.

LS-34 Luncheon Seminar 34**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 08 (Osaka International Convention Center 12F Grande Toque)

Patient Communication in DAT

Chair : Kenichi Fujimoto

Jichi Medical University Station Brain Clinic, Japan

LS-34-1 Considerations for Communication During DAT Implementation

Keita Matsuura

Mie University Hospital Dementia Center, Japan

LS-34-2 Key points in patient communication when introducing and continuing VYALEV

Satoshi Orimo

Kamiyoga Setagaya Street Clinic, Japan

Sponsored by: AbbVie GK

LS-35 Luncheon Seminar 35**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 09 (Osaka International Convention Center 12F Conference Room 1202)

Management of lifestyle diseases as preventive intervention for Alzheimer's disease

Chair : Atsushi Iwata

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

LS-35-1 Hisatomo Kowa

Kobe University Graduate School of Health Sciences, Japan

Sponsored by: Novo Nordisk Pharma Ltd. Medical Affairs Department

LS-36 Luncheon Seminar 36**Jp • En**

May 23 (Fri) 12:00 ~ 13:00 Room 10 (Osaka International Convention Center 11F Conference Room 1101-1102)

Impact of infectious diseases on healthChair : Masahito Yamada
Kudanzaka Hospital, Japan**LS-36-1 Role of VZV reactivation in CNS in adult**Tetsushi Yoshikawa
Department of Pediatrics, Fujita Health University, Japan**LS-36-2 Role of VZV reactivation and what do we expect in the future**Maria Nagel
University of Colorado Anschutz Medical Campus, USA

Sponsored by: GlaxoSmithKline K.K.

LS-37 Luncheon Seminar 37**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 11 (Osaka International Convention Center 8F Conference Room 801-802)

Should we start MAOB inhibitor therapy with monotherapy or in combination with levodopa ?Chair : Takanori Hazama
Department of Neurology, National Hospital Organization Osaka Minami
Medical Center, Japan**LS-37-1 MAO-B inhibitors as adjunctive therapy to L-dopa in early Parkinson's disease**Tetsuya Maeda
Division of Neurology and Gerontology, Department of Internal Medicine, School of
Medicine, Iwate Medical University, Japan**LS-37-2 MAO-B inhibitors as monotherapy in early Parkinson's disease**Hiroshi Nagayama
NTT Medical Center Tokyo Department of Neurology, Japan

Sponsored by: FP Pharmaceutical Corporation

LS-38 Luncheon Seminar 38**Jp**

May 23 (Fri) 12:00 ~ 13:00 Room 12 (Osaka International Convention Center 7F Conference Room 701-702)

Let's catch inborn errors of metabolismChair : Ichiro Yabe
Department of Neurology, Faculty of Medicine and Graduate School of
Medicine, Hokkaido University, Japan**LS-38-1 Mitsuru Kubota**Department of General Pediatrics & Interdisciplinary Medicine, National Center for Child Health
and Development, Japan

Sponsored by: OrphanPacific, Inc.

23

Sponsored Seminar

LS-39 Luncheon Seminar 39**En**

May 23 (Fri) 12:00 ~ 13:00

Room 13 (RIHGA Royal Hotel Osaka 3F Korin 1)

Significance of IL-6 inhibition considering long-term prognosis in NMOSD

Chair : Izumi Kawachi

Department of Neurology, Brain Research Institute, Niigata University, Japan/
Comprehensive Medical Education Center, Niigata University School of
Medicine, Japan**LS-39-1 The immunology of NMOSD**

Sarosh R. Irani

Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA

**LS-39-2 How Satralizumab changed treatment strategy in NMOSD
- Real World Evidence from Japan -**

Kazuo Fujihara

Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of
Medicine / Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research
Institute for Neuroscience, Japan

Sponsored by: Chugai Pharmaceutical Co., Ltd.

LS-40 Luncheon Seminar 40**Jp**

May 23 (Fri) 12:00 ~ 13:00

Room 14 (RIHGA Royal Hotel Osaka 3F Korin 2)

Alzheimer's disease

Chair : Yoshio Ikeda

Department of Neurology, Gunma University Graduate School of Medicine,
Japan**LS-40-1 Safety Management of the Anti-A β Antibody LEQEMBI
- Based on the Experience of Treatment in Clinical Practice**

Akihiro Shindo

Department of Neurology, Mie University Graduate School of Medicine, Japan

Sponsored by: Eisai Co., Ltd. / Biogen Japan Ltd.

LS-41 Luncheon Seminar 41**Jp**

May 23 (Fri) 12:00 ~ 13:00

Room 15 (RIHGA Royal Hotel Osaka 3F Korin 3)

Early diagnosis of ALS

Chair : Ryuji Kaji

Center for Research Administration & Collaboration, Tokushima University,
Japan**LS-41-1 Early diagnosis of ALS: from clinical signs and electrophysiology**

Masahiro Sonoo

Faculty of Medical Technology, Teikyo University, Japan

Sponsored by: Mitsubishi Tanabe Pharma Corporation

LS-42 Luncheon Seminar 42**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 01 (Osaka International Convention Center 5F Large Hall)

Alzheimer's Disease

Chair : Takeshi Ikeuchi

Niigata University, Brain Research Institute, Japan, professor

LS-42-1**The actual state and future prospect on LEQEMBI treatment
- Following my experience at real world-**

Soichiro Shimizu

Department of Geriatric Medicine, Tokyo Medical University, professor

LS-42-2**How Anti-A β Antibody Therapy Will Transform Dementia Care:
Rethinking the Future of Community Healthcare**

Manabu Ikeda

Department of Psychiatry, Osaka University Graduate School of Medicine, professor

Sponsored by: Eisai Co.,Ltd. / Biogen Japan Ltd.

LS-43 Luncheon Seminar 43**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 03 (Osaka International Convention Center 10F Conference Room 1003)

BPSD associated with Alzheimer's disease

Chair : Hidekazu Tomimoto

Saiseikai Meiwa Hospital, Japan

LS-43-1**Challenging Behavioral and Psychological Symptoms of Dementia:
Effective Approaches from Medical and Care Perspectives**

Kenji Wada

Kawasaki Medical School, Japan

Sponsored by: Otsuka Pharmaceutical Co., Ltd.

LS-44 Luncheon Seminar 44**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 04 (Osaka International Convention Center 10F Conference Room 1001-1002)

**Autoimmune diseases with encephalitis symptoms (AE/MOGAD) ;
Antibody testing for early diagnosis up date**

Chair : Kazuo Fujihara

Department of Multiple Sclerosis Therapeutics, Fukushima Medical University
School of Medicine, Japan**LS-44-1****The role of antibody testing in the early diagnosis of autoimmune
encephalitis**

Makoto Hara

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan

24

Sponsored Seminar

LS-44-2

When and how should MOG antibodies be tested?

Yoshiki Takai

Department of Pathology, Tohoku University Hospital, Japan / Department of Neurology,
Tohoku University Graduate School of Medicine, Japan

Sponsored by: Cosmic Corporation Co., Ltd.

LS-45 Luncheon Seminar 45

Jp

May 24 (Sat) 12 : 15 ~ 13 : 15 Room 05 (Osaka International Convention Center 10F Conference Room 1009)

Insights into the Impacts and Mechanisms of L-Dopa in Parkinson's Disease: Exploring the Role of Ongentys

Chair : Tetsuya Maeda

Division of Neurology and Gerontology, Department of Internal Medicine,
School of Medicine, Iwate Medical University, Japan

LS-45-1

Hirohisa Watanabe

Department of Neurology, Fujita Medical University School of Medicine, Japan

Sponsored by: ONO PHARMACEUTICAL CO., LTD.

LS-46 Luncheon Seminar 46

Jp

May 24 (Sat) 12 : 15 ~ 13 : 15 Room 06 (Osaka International Convention Center 10F Conference Room 1008)

Management of Disease Burden in Neurology

Chair : Mamoru Shibata

Tokyo Dental College Ichikawa General Hospital, Japan

LS-46-1

What can be done to understand the burden of migraine

Hisaka Igarashi

Fujitsu Clinic, Japan

LS-46-2

Therapeutic strategies considering disease burden in Parkinson's Disease

Yukihiro Hamada

Izumi City General Hospital, Japan

Sponsored by: AbbVie GK

LS-47 Luncheon Seminar 47**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 07 (Osaka International Convention Center 12F Conference Hall)

Critical Approaches to Preventing MS Progression and Optimizing Treatment

Chairs : Juichi Fujimori

Tohoku Medical and Pharmaceutical University, Japan

Takayuki Kondo

Kansai Medical University Medical Center, Japan

LS-47-1**Imaging Techniques for Reliable Detection of Multiple Sclerosis Progression**

Akifumi Hagiwara

Juntendo University Hospital, Japan

LS-47-2**Comprehensive Assessment of Progression for MS Treatment Optimization**

Masaaki Niino

NHO Hokkaido Medical Center, Japan

Sponsored by: Novartis Pharma K.K.

LS-48 Luncheon Seminar 48**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 08 (Osaka International Convention Center 12F Grande Toque)

Tick-Borne encephalitis

Chair : Hideto Nakajima

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan

LS-48-1

Ichiro Yabe

Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan

Sponsored by: Pfizer Japan Inc.

LS-49 Luncheon Seminar 49**Jp**

May 24 (Sat) 12:15 ~ 13:15 Room 09 (Osaka International Convention Center 12F Conference Room 1202)

Mapping the Future: Overcoming Neurodegenerative Disease through Imaging Diagnostics

Chair : Hitoshi Shimada

Brain Research Institute, Niigata University, Japan

LS-49-1**Neuroimaging biomarkers for ultra-early diagnosis and progression monitoring in neurodegenerative disorders: toward next-generation treatments**

Kazuya Kawabata

Fujita Health University Hospital, Japan

24

Sponsored Seminar

LS-49-2

Role of conventional MRI in the clinical diagnosis of neurodegenerative dementia - insights from CPC and PET examinations

Keita Sakurai

National Center for Geriatrics and Gerontology, Japan

Sponsored by: Splink, inc.

LS-50 Luncheon Seminar 50

Jp

May 24 (Sat) 12:15 ~ 13:15 Room 10 (Osaka International Convention Center 11F Conference Room 1101-1102)

Treatment of EGPA with a Long-term Prognosis and the Role of Mepolizumab

Chair : Sonoko Misawa

Professor, Department of Neurology and Neurological Science,

Institute of Science Tokyo

Associate Professor, Department of Neurology, Chiba University, Japan

LS-50-1

Considering Neuropathy in EGPA: Expectations for Mepolizumab in Treating EGPA

Masaru Yokoe

Director of Neurology, Toyonaka Municipal Hospital, Japan

Sponsored by: GlaxoSmithKline K.K.

LS-51 Luncheon Seminar 51

Jp

May 24 (Sat) 12:15 ~ 13:15 Room 11 (Osaka International Convention Center 8F Conference Room 801-802)

Headache, Vertigo and Dizziness

Chair : Kazutoshi Nishiyama

Department of Neurology, Kitasato University School of Medicine, Japan

LS-51-1

Kampo Medicine for Headache, Vertigo and Dizziness by Neurologists

Yoshiharu Nakae

Department of Neurology, Saiseikai Yokohamashi Nanbu Hospital, Japan

Sponsored by: Tsumura & Co.

LS-52 Luncheon Seminar 52

Jp

May 24 (Sat) 12:15 ~ 13:15 Room 12 (Osaka International Convention Center 7F Conference Room 701-702)

Significance of Amyloid PET

Chair : Riki Matsumoto

Professor, Department of Neurology, Kyoto University Graduate School of

Medicine, Japan

LS-52-1

The Role of Brain SPECT and PET in the New Era of Alzheimer's Disease

Tomotaka Tanaka

Medical Director, Department of Neurology, National Cerebral and Cardiovascular Center, Japan

Sponsored by: Nihon Medi-Physics Co., Ltd.

LS-53 Luncheon Seminar 53**Jp**

May 24 (Sat) 12:15 ~ 13:15

Room 13 (RIHGA Royal Hotel Osaka 3F Korin 1)

Complement and neuroimmune diseases**- Why is complement control necessary now?-**

Chairs : Hiroyuki Murai

Department of Neurology, School of Medicine, International University of Health and Welfare, Japan

Ichiro Nakashima

Department of Neurology, Tohoku Medical and Pharmaceutical University, Japan

LS-53-1**Considering treatments that do not cause waves of MG symptoms****- The need for complement inhibitors -**

Akiyuki Uzawa

Department of Neurology, Graduate School of Medicine, Chiba University, Japan

LS-53-2**NMOSD pathomechanism approaching from the complement system**

Shuhei Nishiyama

Department of Neurology, Tohoku University Hospital, Japan

Sponsored by: Alexion Pharmaceuticals, Inc.

LS-54 Luncheon Seminar 54**Jp**

May 24 (Sat) 12:15 ~ 13:15

Room 14 (RIHGA Royal Hotel Osaka 3F Korin 2)

Parkinson's Disease treatment looking towards the 100-year life

Chair : Taku Hatano

Department of Neurology, Juntendo University Faculty of Medicine, Japan

LS-54-1**To Extend Healthy Life Expectancy of People with PD**

Tadashi Ichikawa

Saitama Prefectural Rehabilitation Center, Japan

LS-54-2**How should we treat the majority of Parkinson disease with elderly, despite the lack of evidence?**

Atsushi Takeda

National Hospital Organization Sendai Nishitaga Hospital, Japan

Sponsored by: Takeda Pharmaceutical Company Limited

LS-55 Luncheon Seminar 55**Jp**

May 24 (Sat) 12:15 ~ 13:15

Room 15 (RIHGA Royal Hotel Osaka 3F Korin 3)

Current status of multiple sclerosis treatment: Reconsidering treatment goals

Chair : Toshiyuki Fukazawa

CEReS Incorporated Medical Institution Sapporo Neurology Hospital, Japan

LS-55-1**Advances in MS Treatment: What are the Current Treatment Goals?**

Chiyoeko Nohara

Tokyo Metropolitan Ebara Hospital, Japan

22

LS-55-2

Update in MS treatment based on life events

Yuko Shimizu

Tokyo Women's Medical University Hospital, Japan

Sponsored by: Biogen Japan

24

ES-01 Evening Seminar 01

 Jp • En

May 22 (Thu) 19:00 ~ 20:30 Room 03 (Osaka International Convention Center 10F Conference Room 1003)

Doctor/Patient/Family Communication in the New Era of Dementia Care

Chairs : Takeshi Iwatsubo

National Center of Neurology and Psychiatry, National Institute of Neuroscience, Japan

Wiesje van der Flier

Alzheimer center Amsterdam, Netherlands

ES-01-1

What is the value of anti-A β antibody drugs for patients and families?

Atsushi Iwata

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

ES-01-2

From EBM to SDM: Expectations for the Future Dementia Care

Takeo Nakayama

Kyoto University School of Public Health, Japan

Panel

Discussion

Takeshi Iwatsubo

National Center of Neurology and Psychiatry, National Institute of Neuroscience, Japan

Wiesje van der Flier

Alzheimer center Amsterdam, Netherlands

Atsushi Iwata

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

Takeo Nakayama

Kyoto University School of Public Health, Japan

Sponsored by: Eli Lilly Japan K.K.

ES-02 Evening Seminar 02

Jp

May 22 (Thu) 19:00 ~ 20:00 Room 04 (Osaka International Convention Center 10F Conference Room 1001-1002)

Rational Decision-Making for Refractory Status Epilepticus

Chair : Kazutaka Jin

Department of Epileptology Tohoku University Graduate School of Medicine, Japan

ES-02-1

Shuichiro Nesige

Department of Clinical Neuroscience and Therapeutics Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan

Sponsored by: Alfresa Pharma Corporation

ES-03 Evening Seminar 03**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 05 (Osaka International Convention Center 10F Conference Room 1009)

Pharmacotherapy for advanced Parkinson's disease

Chair : Masahiko Tomiyama

Department of Neurology, Hirosaki University Graduate School of Medicine,
Japan**ES-03-1 Taku Hatano**

Department of Neurology, Juntendo University Faculty of Medicine, Japan

Sponsored by: Eisai Co., Ltd.

ES-04 Evening Seminar 04**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 06 (Osaka International Convention Center 10F Conference Room 1008)

Latest findings in Lambert-Eaton Myasthenic Syndrome: My future treatment strategy

Chair : Masakatsu Motomura

NAGASAKI INSTITUTE OF APPLIED SCIENCE, Japan

ES-04-1 Ryoji Naganuma

Kashiwaba Hospital, Japan

Sponsored by: DyDo Pharma, Inc.

ES-05 Evening Seminar 05**En**

May 22 (Thu) 19:00 ~ 20:00 Room 07 (Osaka International Convention Center 12F Conference Hall)

Treatment Goals for Myasthenia Gravis: Evolving Options with Fundamental Principles**- What Remains Unchanged, What Needs to Change -**

Chairs : Shunya Nakane

Department of Neurology, Faculty of Medicine, Academic Research Division,
University of Toyama, Japan

Yoko Warabi

Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan

ES-05-1 Reaffirm the fundamental principles of treatment goals for myasthenia gravis

Pushpa Narayanaswami

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

ES-05-2 Advocate for the importance and approach of individualized treatment goal setting

Chongbo Zhao

Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai
Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.

Sponsored by: UCB Japan Co., Ltd.

ES-06 Evening Seminar 06**Jp**

May 22 (Thu) 19:00 ~ 20:30 Room 08 (Osaka International Convention Center 12F Grande Toque)

**Current status and prospects of fluid biomarkers in dementia care
-Expectations for blood biomarkers -**

Chair : Toshihisa Tanaka

Osaka Keisatsu Hospital, Dementia Center, Japan, Director

ES-06-1**Dementia care initiatives at Osaka Keisatsu Hospital**

Yoshiki Sawa

Osaka Keisatsu Hospital, Japan, President of the Hospital

ES-06-2**Current status and prospects of blood biomarkers in dementia disease treatment in the era of disease-modifying therapies**

Takahiko Tokuda

Osaka Metropolitan University Department of Etiology and Diagnostics, Japan, Project Professor

Sponsored by: FUJIREBIO INC. / H.U. Frontier, INC

ES-07 Evening Seminar 07**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 09 (Osaka International Convention Center 12F Conference Room 1202)

Prevention and therapeutic measures of frailty toward the total care of older population : including the significance of zinc supplementation

Chair : Hiroshi Nagayama

Department of Neurology, NTT Medical Center Tokyo, Japan

ES-07-1**Sumito Ogawa**

Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Japan

Sponsored by: Nobelpharma Co., Ltd. / MEDIPAL HOLDINGS CORPORATION

ES-08 Evening Seminar 08**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 10 (Osaka International Convention Center 11F Conference Room 1101-1102)

Anticoagulant Therapy for Stroke Prevention: Deciphering Real-World Data

Chair : Shigeru Fujimoto

Division of Neurology Department of Medicine Jichi Medical University School of Medicine, Japan

ES-08-1**Cardioembolism: Risk Management and Appropriate Anticoagulant Therapy**

Takeo Sato

Department of Stroke, Stroke Center, National Hospital Organization Kagoshima Medical Center, Japan

ES-08-2 Application of the Latest Diagnostic Imaging Technology in Stroke management**Hiroyuki Kawano**

Department of Stroke and Cerebrovascular Medicine, Kyorin University, Japan

Sponsored by: Bristol Myers Squibb K.K. / Pfizer Japan Inc.

ES-09 Evening Seminar 09**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 11 (Osaka International Convention Center 8F Conference Room 801-802)

Effects and Applications of HAL for Neurological Disorders

Chair : Toshio Saito

Division of Child Neurology, Department of Neurology, National Hospital
Organization Osaka Toneyama Medical Center, Japan**ES-09-1 Keiji Yamaguchi**

Vice-President and Director, Department of Neurology, Ichinomiya Nishi Hospital, Japan

Sponsored by: CYBERDYNE.inc

ES-10 Evening Seminar 10**Jp**

May 22 (Thu) 19:00 ~ 20:00 Room 12 (Osaka International Convention Center 7F Conference Room 701-702)

Considering the Issues in PD Treatment: The Importance of Early Intervention

Chair : Shigeki Arawaka

Professor, Department of Internal Medicine IV, Division of Neurology, Osaka
Medical and Pharmaceutical University, Japan**ES-10-1 From the Perspective of comprehensive treatment****Kousuke Baba**Specially Appointed Professor, Department of Neurology, Graduate School of Medicine, Osaka
University, Japan**ES-10-2 From the Perspective of Dysphagia****Makito Hirano**

Professor, Department of Neurology, Kindai University Faculty of Medicine, Japan

Sponsored by: Takeda Pharmaceutical Company Limited.

ES-11 Evening Seminar 11**Jp**

May 22 (Thu) 19:00 ~ 20:30

Room 13 (RIHGA Royal Hotel Osaka 3F Korin 1)

How to properly proceed with anti-amyloid- β antibody therapy for early-stage Alzheimer's disease

Chair : Takayoshi Shimohata

Department of Neurology, Gifu University Graduate School of Medicine, Japan

ES-11-1 Ryoko Ihara

Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

Sponsored by: Eli Lilly Japan K.K.

ES-12 Evening Seminar 12**Jp**

May 22 (Thu) 19:00 ~ 20:00

Room 14 (RIHGA Royal Hotel Osaka 3F Korin 2)

Guiding the Management of ATTRv Amyloidosis: Latest Diagnostic and Treatment Approaches Based on the Updated Amyloidosis Guidelines

Chair : Mitsuharu Ueda

Professor, Department of Neurology, Faculty of Life Sciences, Kumamoto University, Japan

ES-12-1**Yoshiki Sekijima**

Professor, Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Japan

Sponsored by: Alnylam Japan

ES-13 Evening Seminar 13**Jp**

May 22 (Thu) 19:00 ~ 20:00

Room 15 (RIHGA Royal Hotel Osaka 3F Korin 3)

Indications and Strategies for Device-Aided Therapy (DAT) in Parkinson's Disease

Chair : Makoto Shiraishi

Department of Neurology, St. Marianna University School of Medicine, Japan

ES-13-1**Patient Profiles for Considering DAT****Yuta Kajiyama**

Department of Neurology, Kawasaki Medical School, Japan

ES-13-2**Therapeutic Strategies of DAT****Katsuo Kimura**

Department of Neurology, Yokohama City University Medical Center, Japan

Sponsored by: AbbVie GK

ES-14 Evening Seminar 14**En**

May 22 (Thu) 19:00 ~ 20:00

Room 01 (Osaka International Convention Center 5F Large Hall)

Multiple Sclerosis: insights from genetics

Chair : Takuta Matsushita

Kochi Medical School, Department of Neurology, Japan

ES-14-1**Stephen Sawcer**

University of Cambridge, Department of Clinical Neuroscience, UK

Sponsored by: KOTAI Biotechnologies, Inc.